Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Chromatin accessibility of an enhancer that regulates the expression of a disease-associated microRNA is affected in monocytes from patients with systemic lupus erythematosus, highlighting this enhancer as a potential therapeutic target.
New research shows that a recombinant antibody that binds type II collagen protects against the development of arthritis in mice by blocking neutrophil recruitment.
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set to remain an important treatment option for the foreseeable future.
Treatment of patients with arthralgia during the ‘window of opportunity’ could prevent disease development or a severe disease course. This Review summarizes available information on the completed and ongoing prevention trials in rheumatoid arthritis, including patient preferences and future considerations.
This Evidence-Based Guideline presents the first Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis, addressing therapeutic targets, the use of pharmacological and non-pharmacological interventions and monitoring of patients.
In this Review, the authors present epidemiological data relating to the idiopathic inflammatory myopathies and summarize the current understanding of the risk factors associated with these conditions, as well as highlighting areas that require further research.
A single-cell atlas of the human musculoskeletal system could help to improve the understanding of musculoskeletal function in growth, homeostasis, ageing and disease. This Roadmap delineates the steps required and challenges involved in creating such an atlas.
In an observational study, SARS-CoV-2 antibody therapy used as pre-exposure prophylaxis reduced the incidence of COVID-19 in individuals with rheumatic diseases.
New research shows that the FGF10–FGFR1 axis is highly activated in lining fibroblast-like synoviocytes during relapsing rheumatoid arthritis and is a potential therapeutic target.
New research shows that deficiency of the sulfation-related SLC26A2 affects osteocyte formation, and that targeting downstream mediators can ameliorate SLC26A2-deficient osteoporosis.
The autoimmune disease systemic sclerosis is characterized by fibrosis, which is poorly targeted by the use of anti-inflammatory and immunosuppressive drugs. In this Review, the authors describe the fibrotic mechanisms underlying SSc and attempts to develop drugs to specifically target the fibrotic extracellular matrix.
Emerging data suggest that the frequency of long-term opioid use is high among individuals with rheumatic and musculoskeletal diseases, which is of concern given the risks of opioid misuse. But is long-term opioid use really that high or is the situation more complicated?
Placebo responses are prevalent in clinical trials for osteoarthritis, and they hinder the identification of effective new treatments. In this Review, Colloca and Neogi describe various aspects of the placebo phenomenon, and demonstrate how this knowledge can help to improve the design of clinical trials.
In this Review, the authors provide an overview of the therapeutic effects of uricases, outcomes related to gout and its comorbidities in clinical trials and challenges surrounding the use of uricases as potent urate-lowering therapy for the treatment of gout.
In this Perspective, the authors discuss select examples of advancements in high-resolution imaging, functional molecular imaging and artificial intelligence-based analysis that hold promise for addressing current imaging limitations, enabling earlier diagnosis, improved monitoring and ultimately, personalized patient management.
A monoclonal antibody targeting a peptide that replicates the proinflammatory properties of IL-17 has shown potent activity and an acceptable profile of adverse effects in pre-clinical studies.
New findings suggest that liposome-mediated delivery of a specific microRNA inhibitor can restore anti-inflammatory macrophage polarization and reduce joint inflammation in mice.
Although inflammatory arthritis induced by immune-checkpoint inhibitors clinically resembles that of rheumatoid arthritis or psoriatic arthritis, research shows that it differs in its associated T cell response.
